Today-July 1

The Health Sciences Authority (HSA) has granted interim authorization for an antibody drug known as sotrovimab to be used in the treatment of Covid-19 patients. Developed by GlaxoSmithKline (GSK) and Vir Biotechnology, sotrovimab can be used to treat patients aged 18 and older with mild to moderate Covid-19 who do not require supplemental oxygen, but are at risk of progression to severe forms of the disease.“ The at-risk factors include being aged 55 years and above, and/or having comorbidities such as chronic kidney disease, chronic obstructive pulmonary disease, congestive heart failure, diabetes, moderate to severe asthma and obesity,” HSA said on Wednesday (June 30). The interim authorization, given under the Pandemic Special Access Route, comes after HSA reviewed data from an ongoing trial. Sotrovimab was granted emergency use authorisation in the United States on May 26.

Read more at: https://www.todayonline.com/singapore/singapore-gives-interim-authorisation-use-glaxosmithkline-drug-treat-covid-19